Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

The U.S. Supreme Court could make a decision Friday that would rattle Gilead Sciences' newest HIV prevention drug.

(Reuters) -Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover preventive care at no ...

Shares of Gilead Sciences Inc. (GILD) jumped more than 2% on Friday afternoon after the U.S. Supreme Court upheld a part of ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover certain preventive services at no cost to patients in a 6-3 ruling. That’s ...

An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA).

In observance of National HIV Testing Day Friday, several sites across South Florida are offering free rapid HIV testing and ...

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

Yes, the justices upheld a key part of the Affordable Care Act, but they also said our conspiracy theorist Health Secretary ...